PORTLAND, Oregon and PUNE, India, November 22, 2016 /PRNewswire/ -- A new report published by Allied Market Research, titled, "Transcatheter Aortic Valve ImplantationMarket-Global Opportunity Analysis and Industry Forecast, 2014 -2022", projects that the global transcatheter aortic valve implantation market is expected to reach $5,962 million by 2022 growing at a CAGR of 16.5% during 2016 to 2022. Transfemoral implantation is expected to dominate the overall market (in terms of value and volume) throughout the forecast period. Europe held the leading position in the global market (in terms of value and volume) in 2015, and is expected to maintain its lead throughout the study period. (Logo: http://photos.prnewswire.com/prnh/20140911/647229 ) Summary of the Transcatheter Aortic Valve Implantation/Replacement (TAVI/TAVR) Market Report can be accessed on the website at:https://www.alliedmarketresearch.com/tavi-market The TAVI market is in its growth phase, and is mainly driven by rise in prevalence of aortic stenosis and increase in geriatric population. In addition, increase in adoption rate of transcatheter aortic implantation along with new device approvals and improvement of healthcare infrastructure in developing countries are other factors that fuel the market growth. However, high cost of transcatheter aortic valve and its implantation procedures, along with lack of reimbursement and stringent approvals for these devices, hampers the growth of the TAVI market. According to Hemali Narkhede, Manager, Healthcare Research at AMR, "Afterthe U.S. and Europe, Japanholds the largest share for TAVI devices. The large population of elderly above the age of 65 years with aortic stenosis, high adoptionof TAVIdevices for the treatment of aortic stenosis, and favorable reimbursement policiesin the countryare expected to further drive the market growth.""Furthermore, companieshave beenmodifying the TAVR devices according to the needs of patients, for instance,in 2013,Edwards Lifesciences developed smallest-sized version of its SAPIEN XT TAVIvalve, which is ideal for Japanese patients."She added. The report segments the TAVI market on the basis of the approach used for implantation. Mainly, three types of approaches are used to implant the transcatheter aortic valve in patients: transfemoral, transapical, and transaortic implantation. Transfemoral implantation is the standardized TAVI procedure, wherein an artificial valve is implanted through the femoral artery with minimal anesthesia. Patients who have weak and small arteries are unable to undergo this procedure; thus, transapical implantation is preferred, wherein the artificial valve is inserted through the left ventricular apex. Furthermore, transaortic implantation is developed for patients who have weak femoral arteries and poor respiratory function, which makes them unsuitable for transfemoral as well as transapical TAVI procedure as well. In transaortic implantation, the artificial valve is implanted through ministernotomy.